Psoriasis Biosimilars Market Report 2026

The psoriasis biosimilars market size has grown rapidly in recent years. It will grow from $8.16 billion in 2025 to $9.08 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to high cost of reference biologics, limited patient access to treatment, growing prevalence of moderate to severe psoriasis, increasing physician awareness and prescriptions, initial approvals of TNF-alpha inhibitors.

The psoriasis biosimilars market size is expected to see rapid growth in the next few years. It will grow to $13.79 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to launch of new biosimilars for infliximab, etanercept, and adalimumab, expansion of hospital and online pharmacy networks, increasing healthcare expenditure on dermatology, rising adoption of patient assistance programs, growth in clinical trials for novel biosimilars. Major trends in the forecast period include rising adoption of cost-effective psoriasis biosimilars, increased focus on patient access and affordability, growth in subcutaneous and intravenous administration routes, expansion of hospital and retail pharmacy distribution channels, development of targeted therapies for different psoriasis types.

The climbing psoriatic arthritis diagnosis rates are poised to drive the psoriasis biosimilars market forward. Psoriatic arthritis is a persistent autoimmune disorder sparking joint and skin swelling, commonly in those with psoriasis backgrounds. Diagnosis rates are up, especially from refined screening in psoriasis patients that catches early, faint joint signs once overlooked. Psoriasis biosimilars ease psoriatic arthritis with budget-friendly biologic stand-ins, curbing joint flare-ups and skin issues. For example, in August 2025, the National Psoriasis Foundation (NPF), a US patient advocacy non-profit, stated psoriatic arthritis hits about 1 in 3 psoriasis cases, impacting 2.4 million Americans; over 15% of psoriasis sufferers have undetected psoriatic arthritis, underscoring better detection amid gaps. Thus, the rising psoriatic arthritis diagnoses are fueling the psoriasis biosimilars market.

Leading firms in the psoriasis biosimilars market are rolling out fresh options like biosimilars for plaque psoriasis to widen access, trim expenses, and lift results. Biosimilars for plaque psoriasis offer economical, near-identical swaps for reference biologics tackling the ongoing skin autoimmune issue with red, flaky patches. For instance, in May 2025, Sandoz Group AG, a Switzerland-based generics and biosimilars specialist, debuted the Pyzchiva autoinjector - the inaugural commercial ustekinumab biosimilar auto-device. Approved for adult plaque psoriasis, psoriatic arthritis, and Crohn's, plus kids over six (60+ kg) with plaque psoriasis, it boosts compliance and life quality via precise auto-dosing, less pain, slim profile, and easy storage for hassle-free self-use.

In September 2023, Sandoz Group AG, a Switzerland pharma player, teamed with Samsung Bioepis to market the SB17 (ustekinumab) biosimilar. This alliance taps both strengths to deliver the plaque psoriasis treatment across Europe and North America. It broadens reach to quality, affordable immunology care, cementing Sandoz's biosimilars dominance. Samsung Bioepis is a South Korea biopharma focused on biosimilars, including plaque psoriasis therapies.

Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.

North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the psoriasis biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the psoriasis biosimilars market by increasing the cost of imported biologics, reference molecules, and active pharmaceutical ingredients. Hospital pharmacies and retail distribution channels in regions like North America and Europe, which depend on imports, are most affected. This has led to higher treatment costs and potential delays in patient access. On the positive side, tariffs have encouraged local manufacturing, boosted investment in domestic biosimilar production, and promoted innovation in cost-effective psoriasis therapies.

The psoriasis biosimilars market research report is one of a series of new reports that provides psoriasis biosimilars market statistics, including psoriasis biosimilars industry global market size, regional shares, competitors with a psoriasis biosimilars market share, detailed psoriasis biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the psoriasis biosimilars industry. This psoriasis biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Psoriasis biosimilars are biologic drugs developed to closely replicate the structure, function, safety, and efficacy of approved reference biologics for treating moderate to severe psoriasis. These biosimilars offer a more affordable alternative to original biologics, increasing patient access to advanced therapies without compromising quality or clinical outcomes.

The main drug classes in psoriasis biosimilars include TNF-alpha inhibitors, infliximab, etanercept, adalimumab, and other biosimilars. TNF-alpha inhibitors are biologics that block tumor necrosis factor-alpha (TNF-α), a key protein driving inflammation in psoriasis. They are used to treat various forms of psoriasis, including plaque, guttate, inverse, and pustular psoriasis, and are administered via subcutaneous, intravenous, oral, and topical routes. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The psoriasis biosimilars market consists of sales of tumor necrosis factor inhibitors, monoclonal antibodies, subcutaneous and intravenous formulations, subcutaneous injections, and interleukin inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.